ITGB7

Across TCGA pan-cancer cohorts, ITGB7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ITGB7 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ITGB7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ITGB7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

GBM, PDAC, and LUAD are the cancer types where ITGB7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.165	0.740	.038	6	view →
PDAC	DFS	Median	III,IV	1.000	0.491	.017	3	view →
LUAD	OS	Median	III,IV	0.246	0.654	.042	2	view →
LSCC	DFS	Tertile	All	1.000	0.606	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ITGB7–GBM (OS)

Open the GBM breakdown →